UV-4B 3 mg + UV-4B 10 mg + UV-4B 30 mg + UV-4B 90 mg + UV-4B 180 mg + UV-4B 360 mg + UV-4B 720 mg + UV-4B 1000 mg + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Viral Infection
Conditions
Viral Infection
Trial Timeline
Jul 1, 2014 → Sep 1, 2015
NCT ID
NCT02061358About UV-4B 3 mg + UV-4B 10 mg + UV-4B 30 mg + UV-4B 90 mg + UV-4B 180 mg + UV-4B 360 mg + UV-4B 720 mg + UV-4B 1000 mg + Placebo
UV-4B 3 mg + UV-4B 10 mg + UV-4B 30 mg + UV-4B 90 mg + UV-4B 180 mg + UV-4B 360 mg + UV-4B 720 mg + UV-4B 1000 mg + Placebo is a phase 1 stage product being developed by Emergent BioSolutions for Viral Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02061358. Target conditions include Viral Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02061358 | Phase 1 | Completed |
Competing Products
17 competing products in Viral Infection